Investment in company’s Alnwick base

Paul Quigley, head of API development and bioanalytical services, at Arcinova's facility in Alnwick.
Paul Quigley, head of API development and bioanalytical services, at Arcinova's facility in Alnwick.

An Alnwick-headquartered company working in the pharmaceutical industry has made a major investment in its manufacturing facility.

Arcinova, which provides both end-to-end solutions and standalone services to pharmaceutical and biotech companies, has announced that it has introduced two new 20-litre GMP vessel streams to its Active Pharmaceutical Ingredient (API) manufacturing facility.

The introduction of the two new streams means that the firm can now offer fully-integrated drug-substance and drug-product capabilities on one site.

Paul Quigley, head of API development and bioanalytical services, said: “The introduction of the 20-litre streams forms part of our business growth strategy and will enable us to further enhance the service Arcinova offers our global customer base.

“Our ability to offer fully-integrated drug-substance and drug-product capabilities on one site is a major advantage for our customers and allows us to react more quickly and nimbly to client requirements, and provide security of supply.”

Managing director Ian Shott added: “The installation of the new 20-litre streams at our Alnwick site is part of a program of continued investment in our capabilities.

“Since the company was launched in 2016, we have built on the world-class facilities of the site and the legacy of its former owners, Covance, and the growth of our API department is a key part of this.”

Launched in February 2016, Arcinova operates from a 15,000 m2 facility on a 34-acre site, which has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a rare range of on-site capabilities.